FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Tevimbra is under clinical development by BeiGene and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC).

BI-765049 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Metastatic Colorectal Cancer.

Opdivo Qvantig is approved for solid tumors, including melanoma, renal cell carcinoma, and non-small cell lung cancer. The ...

On December 27, 2024, subcutaneous nivolumab (Opdivo Qvantig) was approved by the FDA in all previously approved adult solid ...

This page includes links to articles highlighting the top gastrointestinal cancer research published on Cancer Therapy ...

CuraTeQ Biologics s.r.o., a step-down subsidiary of Aurobindo Pharma, announced that it has obtained marketing authorisation from UK's Medicines and Healthcare products Regulatory Agency (MHRA) for ...

Bevacizumab is used in the treatment of multiple cancers including metastatic colorectal cancer, recurrent or metastatic non-squamous non-small cell lung cancer, advanced and/or metastatic renal cell ...

Hyderabad: CuraTeQ Biologics s.r.o., a step-down subsidiary of Aurobindo Pharma Limited, has announced that it has obtained ...

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with ...

Aurobindo Pharma announced that its subsidiary, CuraTeQ Biologics s.r.o., has received marketing authorization from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for Bevqolva, ...

On Friday (December 20), shares of Aurobindo Pharma Ltd ended at ₹1,240.70, down by ₹14.70, or 1.17% on the BSE.